Literature DB >> 10859389

Inverse relationship between the expression of the human papillomavirus type 16 transcription factor E2 and virus DNA copy number during the progression of cervical intraepithelial neoplasia.

M Stevenson1, L C Hudson, J E Burns, R L Stewart, M Wells, N J Maitland.   

Abstract

The human papillomavirus type 16 (HPV-16) status of 43 cervical biopsies, which had been characterized histologically as normal, various grades of cervical intraepithelial neoplasia (CIN) and invasive squamous cell carcinoma, was examined by using (i) a novel antibody against the HPV-16 E2 protein, (ii) sensitive HPV-16 DNA in situ hybridization and (iii) microdissection/PCR for the E2 ORF. The data indicate that E2 protein expression is highest in koilocytes in lower-grade CIN (I), but decreases with increasing grade, whereas the detection of HPV DNA is delayed until CIN I/II, rising to the highest levels in carcinoma cells. Co-localization of E2 with HPV-16 DNA-positive cells was most commonly observed in koilocytes in CIN II lesions. PCR analyses of microdissected epithelium from the same or serial sections indicated that E2 ORFs were retained in an intact form in a number of higher-grade CIN lesions and invasive carcinomas.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10859389     DOI: 10.1099/0022-1317-81-7-1825

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  15 in total

Review 1.  The causal relation between human papillomavirus and cervical cancer.

Authors:  F X Bosch; A Lorincz; N Muñoz; C J L M Meijer; K V Shah
Journal:  J Clin Pathol       Date:  2002-04       Impact factor: 3.411

2.  Stability of the human papillomavirus type 18 E2 protein is regulated by a proteasome degradation pathway through its amino-terminal transactivation domain.

Authors:  S Bellanger; C Demeret; S Goyat; F Thierry
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

3.  Tumor suppressor or oncogene? A critical role of the human papillomavirus (HPV) E2 protein in cervical cancer progression.

Authors:  Sophie Bellanger; Chye Ling Tan; Yue Zhen Xue; Sébastien Teissier; Françoise Thierry
Journal:  Am J Cancer Res       Date:  2011-01-24       Impact factor: 6.166

4.  A synthetic E7 gene of human papillomavirus type 16 that yields enhanced expression of the protein in mammalian cells and is useful for DNA immunization studies.

Authors:  Angel Cid-Arregui; Victoria Juárez; Harald zur Hausen
Journal:  J Virol       Date:  2003-04       Impact factor: 5.103

5.  Human papillomavirus type 16 integration in cervical carcinoma in situ and in invasive cervical cancer.

Authors:  Hugo Arias-Pulido; Cheri L Peyton; Nancy E Joste; Hernan Vargas; Cosette M Wheeler
Journal:  J Clin Microbiol       Date:  2006-05       Impact factor: 5.948

6.  The Papillomavirus E2 protein binds to and synergizes with C/EBP factors involved in keratinocyte differentiation.

Authors:  Dirk Hadaschik; Korinna Hinterkeuser; Monika Oldak; Herbert J Pfister; Sigrun Smola-Hess
Journal:  J Virol       Date:  2003-05       Impact factor: 5.103

7.  Dimerization of the human papillomavirus type 16 E2 N terminus results in DNA looping within the upstream regulatory region.

Authors:  Elena E Hernandez-Ramon; Julie E Burns; Wenke Zhang; Hannah F Walker; Stephanie Allen; Alfred A Antson; Norman J Maitland
Journal:  J Virol       Date:  2008-03-12       Impact factor: 5.103

8.  The human papillomavirus type 18 E2 protein is a cell cycle-dependent target of the SCFSkp2 ubiquitin ligase.

Authors:  Sophie Bellanger; Chye Ling Tan; Wenlong Nei; Ping Ping He; Françoise Thierry
Journal:  J Virol       Date:  2010-01       Impact factor: 5.103

Review 9.  HPV as a model for the development of prophylactic and therapeutic cancer vaccines.

Authors:  Raed N Samara; Samir N Khleif
Journal:  Curr Mol Med       Date:  2009-08       Impact factor: 2.222

10.  The human papillomavirus type 8 E2 protein suppresses beta4-integrin expression in primary human keratinocytes.

Authors:  Monika Oldak; Hans Smola; Monique Aumailley; Francisco Rivero; Herbert Pfister; Sigrun Smola-Hess
Journal:  J Virol       Date:  2004-10       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.